![Jonathan Freeman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 33 471 $ in data 30/06/2026
Jonathan E.
Freeman was the founder of Anthos Therapeutics, Inc., founded in 2019, serving as Chief Operating Officer from 2019 to 2025.
Dr. Freeman currently works at Phio Pharmaceuticals Corp.
as an Independent Director since 2017.
Former jobs include Director-Mergers & Acquisitions at Baxter Healthcare Corp.
from 2005 to 2008, Director & Vice President at Swiss-PLG, Senior Vice President & Head-Strategy Development at Merck KGaA from 2013 to 2016, Head-Licensing at EMD Serono, Inc. from 1999 to 2005, Chief Business Officer at Vedanta Biosciences, Inc. from 2017 to 2018, and Senior Advisor at Blackstone Life Sciences Advisors LLC.
Education includes undergraduate and graduate degrees from the University of Cambridge and an MBA from Webster University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 05/02/2026 | 32.655 ( 0,28% ) | 33 471 $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| PHIO PHARMACEUTICALS CORP. | Direttore/Membro del Consiglio | 07/06/2017 |
| Società | Posizione | Fine |
|---|---|---|
Anthos Therapeutics, Inc.
 Anthos Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutic options for the treatment of cardiovascular metabolic diseases | Fondatore | 01/09/2025 |
Vedanta Biosciences, Inc.
 Vedanta Biosciences, Inc. BiotechnologyHealth Technology Develops microbial therapies that address the human immune system | Corporate Officer/Principal | 01/06/2018 |
| MERCK KGAA | Corporate Officer/Principal | 01/01/2016 |
Baxter Healthcare Corp.
 Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Develops, manufactures and distributes hospital supplies and medical technologies | Corporate Officer/Principal | 01/01/2008 |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology Develops recombinant prescription medicines | Corporate Officer/Principal | 01/01/2005 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 10 |
|---|---|
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Develops, manufactures and distributes hospital supplies and medical technologies | Health Technology |
Merck KGaA
 Merck KGaA Pharmaceuticals: MajorHealth Technology Engages in the manufacturing of pharmaceutical and chemical products | Health Technology |
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Webster University
 Webster University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology Develops recombinant prescription medicines | Health Technology |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Develops microbial therapies that address the human immune system | Health Technology |
Phio Pharmaceuticals Corp.
 Phio Pharmaceuticals Corp. BiotechnologyHealth Technology Develops RNAi-based medical technologies and therapies | Health Technology |
Swiss-PLG | |
Blackstone Life Sciences Advisors LLC
 Blackstone Life Sciences Advisors LLC Investment ManagersFinance Blackstone Life Sciences invests in companies located across the globe. The firm targets companies operating in the fields on pharmaceutical, biotechnology and medical technology sectors. It provides financing for growth stage transactions. | Finance |
Anthos Therapeutics, Inc.
Anthos Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutic options for the treatment of cardiovascular metabolic diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
